-
BioChallenge Startup Competition + Louisiana University Technology Showcase
Date and Time
Wednesday Nov 16, 2016
9:00 AM - 1:00 PM CSTWednesday November 16
9:00am - 1:00pmLocation
The Joy Theater
1200 Canal Street,
New Orleans, LA 70112Fees/Admission
Free
Website
Contact Information
programs@neworleansbio.com
Send EmailBioChallenge Startup Competition + Lo...Description
Louisiana University Technology Showcase Statewide research institutions feature new license-ready technologies that have applications in numerous industries. Learn about the advanced research in cancer, advanced materials, and more -- and maybe even find a technology that you can help move from the lab to the market. This showcase is ultimately aimed at facilitating more rapid translation of groundbreaking new regional discoveries.
Participating institutions include:
Louisiana Tech University
LSU
LSU AgCenter
LSU Health New Orleans
Nicholls State University
Tulane University
University of New Orleans
Xavier University of Louisiana
Delgado Community College
Followed by the 5th Annual BioChallenge Startup Pitch Competition -- Four Louisiana startups will pitch to experienced investors and industry professionals for over $50,000 in prizes. The four finalists from New Orleans and Shreveport are: CARRE BIODIAGNOSTICS Carre is focused on a simple blood test to identify chronic kidney disease patients with coronary artery disease who are at high risk for heart attacks, allowing for earlier treatment, better outcomes, and reduced costs. CHOSEN DIAGNOSTICS A personalized medicine startup, Chosen’s first product is a biomarker test that can diagnose a common and life-threatening gastrointestinal disease in preterm infants with significantly higher accuracy than current options. GRAPHENO Developing innovative graphene solutions, Grapheno’s lead product is a conductive coating which protects sensitive electronics by absorbing harmful and unnecessary electromagnetic radiation. SEGUE THERAPEUTICS Segue is dedicated to the discovery and medical use of repurposed drugs (approved drugs for new indications), and the company is initially focused on developing a new treatment for pancreatic cancer.Tell a Friend